Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) and Roche (SWX: RO, ROG; OTCQX: RHHBY) announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds USD 300 million.
Evotec will be responsible for conducting Phase II studies for EVT 101, a compound originally discovered by Roche and Click here to read more.. »
The higher incidence of chronic illnesses in Europe and the consequent increase of patient population in intensive care units has amplified the need for equipment that measure vital signs such as blood pressure during surgeries. This rise in the number of people requiring critical care has escalated the demand for catheters and transducers.
New analysis from Frost & Sullivan (
), Click here to read more.. »
Individuals with diastolic blood pressure under 70 mm Hg coupled with an elevated systolic blood pressure may have a greater risk of heart attack and stroke than indicated by the systolic blood pressure values alone, according to a UC Click here to read more.. »
